Table 2.
COVID-19-associated risk factors in HCP
| Characteristics | Number of patients (%) |
| Sex | |
| Male | 43 (51.2%) |
| Female | 41 (48.8%) |
| Cancer type | |
| Lung cancer | 29 (34.5%) |
| Head and neck cancer | 9 (10.7%) |
| Renal cell cancer | 1 (1.2%) |
| Bladder cancer | 1 (1.2%) |
| Breast cancer | 10 (11.9%) |
| Mesothelioma | 1 (1.2%) |
| Colorectal cancer | 3 (3.6%) |
| Pancreatic cancer | 7 (8.3%) |
| Oesophageal cancer | 2 (2.4%) |
| Gastric cancer | 2 (2.4%) |
| Glioblastoma | 2 (2.4%) |
| Cancer of unknown primary | 6 (7.1%) |
| Cholangiocellular carcinoma | 1 (1.2%) |
| Hepatocellular carcinoma | 2 (2.4%) |
| Sarcoma | 6 (7.1%) |
| Glioma low grade | 1 (1.2%) |
| Neuroendocrine carcinoma | 1 (1.2%) |
| Median age (range), years | 61 (18–86) |
| Type of cancer therapy | |
| No anticancer therapy | 3 (3.6%) |
| Immunotherapy | 23 (27.4%) |
| Chemotherapy | 27 (31.1%) |
| Targeted therapy | 1 (1.2%) |
| Chemotherapy plus targeted therapy | 11 (13.1%) |
| Immunotherapy plus targeted therapy | 3 (3.6%) |
| Immunotherapy plus chemotherapy | 16 (19%) |
| Palliative setting | |
| No | 10 (11.9%) |
| Yes | 74 (88.1%) |
| Outpatient treatment | |
| No | 47 (77.0%) |
| Yes | 28 (23.0%) |
HCP, healthcare professional.